Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Expected to Post Earnings of -$0.08 Per Share
Equities research analysts expect Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to post ($0.08) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Conatus Pharmaceuticals’ earnings. The highest EPS estimate is $0.09 and the lowest is ($0.27). Conatus Pharmaceuticals posted earnings per share of ($0.31) in the same quarter last year, which indicates a positive year-over-year growth rate of 74.2%. The company is expected to report its next earnings report on Tuesday, November 14th.
Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.02. The firm had revenue of $10 million during the quarter, compared to the consensus estimate of $9.33 million. During the same period in the previous year, the company earned ($0.30) EPS.
Several research analysts have recently issued reports on the stock. Aegis restated a “buy” rating and set a $11.00 price objective on shares of Conatus Pharmaceuticals in a report on Monday, May 15th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Conatus Pharmaceuticals in a report on Thursday, June 29th. Stifel Nicolaus restated a “buy” rating and set a $10.00 price objective on shares of Conatus Pharmaceuticals in a report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Finally, ValuEngine upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 24th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $13.39.
A number of hedge funds have recently modified their holdings of CNAT. Renaissance Technologies LLC boosted its stake in shares of Conatus Pharmaceuticals by 193.5% in the fourth quarter. Renaissance Technologies LLC now owns 183,700 shares of the biotechnology company’s stock valued at $968,000 after buying an additional 121,100 shares in the last quarter. Nationwide Fund Advisors purchased a new stake in shares of Conatus Pharmaceuticals during the first quarter valued at $413,000. Acadian Asset Management LLC purchased a new stake in shares of Conatus Pharmaceuticals during the first quarter valued at $854,000. Bank of New York Mellon Corp boosted its stake in shares of Conatus Pharmaceuticals by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company’s stock valued at $464,000 after buying an additional 1,655 shares in the last quarter. Finally, Courage Capital Management LLC boosted its stake in shares of Conatus Pharmaceuticals by 25.0% in the first quarter. Courage Capital Management LLC now owns 125,000 shares of the biotechnology company’s stock valued at $721,000 after buying an additional 25,000 shares in the last quarter. 22.96% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/15/conatus-pharmaceuticals-inc-nasdaqcnat-expected-to-post-earnings-of-0-08-per-share.html.
Conatus Pharmaceuticals (CNAT) opened at 5.16 on Tuesday. The company has a 50-day moving average price of $5.88 and a 200-day moving average price of $5.63. The firm’s market capitalization is $154.82 million. Conatus Pharmaceuticals has a 1-year low of $1.45 and a 1-year high of $9.40.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.